The Bear Cave #340

Wolfpack Research reported Flotek Industries (FTK) lost a $400M contract, potentially halving its backlog. Fugazi Research criticized Aeva Technologies (AEVA) as a struggling startup. Bristlemoon Research argued Macy's (M) is overvalued. L3Harris (LHX) CEO departed over conduct violations. Ameresco (AMRC) CFO and GC resigned. Viking Therapeutics (VKTX) COO and Merit Medical (MMSI) COO departed. Boston Beer (SAM) CFO is stepping down. Edwin Dorsey predicts long-term trouble for DraftKings (DKNG)

Original reporting
Published Aug 23, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 23, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Bear Cave #340 — source image
Decision brief

The 30-second read

$FTKBearishLow
01

Why it matters

Overall sentiment is negative due to multiple executive exits and critical research reports, suggesting short‑bias for affected tickers.

02

Market read

The article provides a collection of negative catalysts for several U.S. stocks, but offers no new primary disclosures.

03

What to watch

Potential hidden operational issues not disclosed in the brief.

Relevance 4/10Novelty 2/10Timing: none

Background

The Bear Cave newsletter aggregates recent activist research, executive departures, and opinion pieces.

Company-level read

Ticker impact

$FTKBearishMedium confidence
Context

Wolfpack Research alleges Flotek Industries failed to disclose the cancellation of a $400M PREPA contract, potentially wiping out over 50% of its backlog.

Expected impact

downside pressure

Evidence & confidence

Backlog loss of >50% is material for a $894M market cap company.

$AEVABearishMedium confidence
Context

Fugazi Research calls Aeva Technologies a "bleeding startup" and highlights $11.9M insider selling after its AI-data-center announcement.

Expected impact

downside risk

Evidence & confidence

Research report and insider sell signal weakness.

$MBearishLow confidence
Context

Bristlemoon Research labels Macy's as an "attractive short" despite recent comparable sales improvement.

Expected impact

potential decline

Evidence & confidence

Research opinion without new fundamentals.

$LHXBearishLow confidence
Context

L3Harris Technologies CEO resigned immediately after board discovered code‑of‑conduct violations.

Expected impact

possible dip

Evidence & confidence

CEO exit is material but impact uncertain.

$AMRCBearishLow confidence
Context

Ameresco CFO and CAO are stepping down within a month, with the General Counsel also resigning.

Expected impact

downside risk

Evidence & confidence

Leadership churn often pressures stock.

$VKTXBearishLow confidence
Context

Viking Therapeutics COO disappeared from the website with no disclosure.

Expected impact

potential decline

Evidence & confidence

Lack of transparency is a red flag.

$SAMNeutralLow confidence
Context

Boston Beer CFO announced his resignation effective September 30, with an interim CFO appointed.

Expected impact

minimal impact

Evidence & confidence

Routine CFO change without immediate financial effect.

$MMSINeutralLow confidence
Context

Merit Medical Systems COO gave notice to resign for good reason, effective March 2027 after his position was eliminated.

Expected impact

minimal impact

Evidence & confidence

Resignation effective years away.

Market effects

Activist reports may increase short‑interest in industrial and tech sectors.

No specific regional effect identified.

Limited to U.S. listed companies mentioned.

Counterpoint

Some investors may view the resignations as opportunities for fresh leadership.

Key entities

  • Wolfpack Research

    Published critical report on Flotek Industries.

  • Fugazi Research

    Published critical report on Aeva Technologies.

Related articles

$VKTXMedAI 8/10

Viking Therapeutics initiates oral maintenance dosing study

Viking Therapeutics (VKTX) began Part 2 of a maintenance dosing study for VK2735, its obesity treatment. The trial will test oral and subcutaneous dosing regimens in 195 adults with obesity. Part 1 showed positive results. Part 2 results are expected in 2027. Viking is also running two Phase 3 studies, VANQUISH-1 and VANQUISH-2, for subcutaneous VK2735.

$VKTXHighAI 8/10

Significant stock movers of September: Viking soars, Longeveron slides

Viking Therapeutics (VKTX) rose 24% in September after positive Phase 1 data for VK2735, a weight-loss drug, but ended the month down 3.18% due to a $575M financing. Longeveron (LGVN) fell 64% after its stem cell therapy failed a Phase 2b trial, triggering a strategic review. The broader biotech sector declined 3.5% in September.

$VKTXMedAI 8/10

Viking Therapeutics (VKTX) On Fresh VK2735 Data And New Funding Still Looks Pricey

Viking Therapeutics (VKTX) reported positive top-line data for its VK2735 obesity maintenance study and raised over US$500m. Despite this, the share price has declined 15.8% in 7 days and 22.7% in 90 days, trading at US$29.94. The company's P/B ratio of 8.6x is significantly higher than its peers, suggesting high expectations for future value creation. A DCF model estimates the stock's value at US$7.34, indicating potential overvaluation.

$LHXHigh

L3Harris Technologies (LHX) After The $6b THAAD Win Looks Mispriced

L3Harris Technologies (LHX) secured a $6b contract from Lockheed Martin for THAAD propulsion production. Despite a 22.3% YTD share price decline, analysts estimate a fair value of $342.36, suggesting undervaluation. Growth prospects are tied to U.S. defense budget increases and missile/space programs, but risks include budget constraints and supply chain issues.